X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
https://www.globenewswire.com//news-release/2024/03/13/2845924/0/en/Mesoblast-Successfully-Completes-Placement-and-Accelerated-Entitlement-Offer.html
https://www.globenewswire.com//news-release/2024/02/28/2837527/0/en/Mesoblast-Reports-Financial-Results-and-Operational-Update-for-Half-Year-Ended-December-31-2023.html
https://www.globenewswire.com//news-release/2024/02/15/2829545/0/en/United-States-Food-Drug-Administration-FDA-Grants-Mesoblast-Orphan-Drug-Designation-for-Revascor-Rexlemestrocel-L-in-Children-With-Congenital-Heart-Disease.html
https://www.globenewswire.com/news-release/2024/01/31/2820682/0/en/Appendix-4C-Quarterly-Activity-Report-for-Quarter-Ended-December-31-2023.html
https://www.globenewswire.com//news-release/2024/01/18/2812039/0/en/United-States-Food-Drug-Administration-FDA-Grants-Mesoblast-Rare-Pediatric-Disease-Designation-for-Revascor-Rexlemestrocel-L-in-Children-With-Congenital-Heart-Disease.html
https://www.globenewswire.com//news-release/2023/11/26/2785808/0/en/Mesoblast-Files-for-Orphan-Drug-and-Pediatric-Rare-Disease-Designations-for-Rexlemestrocel-L-as-Treatment-for-Severe-Congenital-Heart-Disease.html
https://www.globenewswire.com//news-release/2023/11/21/2784503/0/en/Mesoblast-Partners-With-Blood-and-Marrow-Transplant-Clinical-Trials-Network-BMT-CTN-on-Pivotal-Trial-in-Adults-With-SR-aGVHD.html
https://www.globenewswire.com//news-release/2023/10/31/2769779/0/en/Appendix-4C-Quarterly-Activity-Report-for-Quarter-Ended-September-30-2023.html
https://www.fiercebiotech.com/biotech/take-three-mesoblast-plots-path-market-twice-rejected-cell-therapy
Market Place
Share 
